| Identification | Back Directory | [Name]
Finerenone (BAY 94-8862) | [CAS]
1050477-31-0 | [Synonyms]
BAY948862
BAY 94-8862
Finerenone (BAY 94-8862)
(4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide
1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)- | [Molecular Formula]
C21H22N4O3 | [MDL Number]
MFCD29047135 | [MOL File]
1050477-31-0.mol | [Molecular Weight]
378.42 |
| Chemical Properties | Back Directory | [Boiling point ]
554.7±50.0 °C(Predicted) | [density ]
1.29±0.1 g/cm3(Predicted) | [storage temp. ]
-20°C | [solubility ]
DMF: 10 mg/ml DMSO: 3 mg/ml Ethanol: insol PBS (pH 7.2): insol | [form ]
solid | [pka]
14.76±0.40(Predicted) | [color ]
White to off-white | [λmax]
255 nm | [InChI]
InChI=1S/C21H22N4O3/c1-5-28-21-18-17(14-7-6-13(9-22)8-15(14)27-4)16(20(23)26)12(3)25-19(18)11(2)10-24-21/h6-8,10,17,25H,5H2,1-4H3,(H2,23,26)/t17-/m1/s1 | [InChIKey]
BTBHLEZXCOBLCY-QGZVFWFLSA-N | [SMILES]
N1C2=C(C(OCC)=NC=C2C)[C@H](C2=CC=C(C#N)C=C2OC)C(C(N)=O)=C1C |
| Hazard Information | Back Directory | [Description]
Finerenone(1050477-31-0) is a novel mineralocorticoid receptor antagonist that has the effect of delaying the progression of chronic kidney disease. Some people may be aware of two other mineralocorticoid receptor antagonists: the diuretic antihypertensive drug spironolactone, and eplerenone.Finerenone is their cognate derivative and is a third-generation mineralocorticoid receptor antagonist. So far, finerenone is the only nonsteroidal mineralocorticoid receptor antagonist to be FDA approved. ?Finerenone was granted FDA approval on 9 July 2021, followed by the EMA approval on 11 March 2022. | [Uses]
Finerenone is the first non-steroidal selective mineralocorticoid receptor antagonist, which can be used for the treatment of diabetic nephropathy, chronic kidney disease and end-stage renal disease. It can reduce the proteinuria of patients and improve the glomerular filtration rate. | [Indications]
Finerenone is used for the treatment of adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D). Finerenone's indication is to reduce the risk of sustained estimated glomerular filtration rate decline, end-stage renal disease, end-stage renal disease, cardiovascular death, non-fatal myocardial infarction, and risk of hospitalisation for heart failure. | [Brand name]
Finerenone is sold under the brand name Kerendia and Firialta. | [Biological Activity]
Finerenone (FIN, BAY 94-8862) is a highly selective, orally active, nonsteroidal antagonist of mineralocorticoid receptor (MR) with IC50 of 18 nM. Finerenone has the potential to study cardio-renal diseases such as type 2 diabetes and chronic kidney disease. | [Synthesis]
Synthesis scheme of finerenone: Firstly, benzaldehyde 20.1 was condensed with acetoacetamide under Knoevenagel condensation conditions to give high yield of ketone 20.2 of undetermined structure.Meanwhile, pyridinyl chloride 20.3 was treated at high temperature with strong alkali conditions followed by treatment with strong acid at low temperature to give filterable pyridinone solid 20.4.
Addition of 20.2 to a heated isobutanol solution of 20.4 resulted in a condensation-cyclisation reaction to give the nitrogen-containing heterocyclic compound 20.5 in good yield. The conversion of the pyridone to the corresponding ether was achieved by treating the pyridone with 1,1,1-triethoxyethane under acidic conditions. Some of the synthetic methods for fenaridones were carried out by chromatographic separation of the racemate 20.6, while a recent patent reports a classical splitting using tartaric acid derived salts. In one example, 20.6 was reacted with p-toluoyl-d-tartaric acid in a mixture of ethanol and water to give the target enantiomer in 78% enantiomeric excess, which was purified to 99% enantiomeric excess by re-suspension in ethanol and water to ultimately give 20.7 in about 41% yield. Adjusting the pH in water and ethanol with sodium carbonate gave the free base of fenaridone (20) in 97% yield.
 | [in vivo]
Finerenone (BAY 94-8862) lowers albuminuria by >40% and significantly reduces systolic blood pressure (SBP) in Munich Wistar Fr?mter (MWF) rat. | [Mode of action]
Finerenone is a Nonsteroidal Mineralocorticoid-Receptor Antagonist. The mechanism of action of finerenone is as a Mineralocorticoid Receptor Antagonist. Finerenone inhibits the effects of mineralocorticoids like aldosterone and cortisol when the MR is overactivated, possibly reducing inflammation and fibrosis in the heart and kidney. | [References]
Kolkhof, P., Hartmann, E., Freyberger, A., et al.Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage. Am. J. Nephrol. 52(8), 642-652 (2021).
DOI: 10.1159/000516213
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. |
|
| Company Name: |
Jia Xing Isenchem Co.,Ltd
|
| Telephone: |
0573-85285100 18627885956 |
| Website: |
https://www.chemicalbook.com/ShowSupplierProductsList14265/0_EN.htm |
| Company Name: |
Adamas Reagent, Ltd.
|
| Telephone: |
4006009262 13023226327 |
| Website: |
http://www.tansoole.com |
|